Medicenna Therapeutics Corp. Research and Development Expense
Medicenna Therapeutics Corp. (MDNAF) reported Research and Development Expense of CAD 9.30 million for the 12-month period ending 2023-03-31, per its 20-F filed 2023-06-27.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2023-06-27
| Period end | Research And Development Expense 12 month |
|---|---|
| 2023-03-31 | 9.30M CAD 20-F · filed 2023-06-27 |
| 2022-03-31 | 14.72M CAD 20-F · filed 2023-06-27 |
| 2021-03-31 | 10.87M CAD 20-F · filed 2023-06-27 |
| 2020-03-31 | 5.87M CAD 20-F · filed 2022-06-22 |